Johnson & Johnson’s Biosense Webster today announced the start of patient cases with the investigational Laminar LAAX system.
In November 2023, Johnson & Johnson MedTech completed a $400 million acquisition of Laminar, With that buy, the company brought in Laminar’s left atrial appendage elimination (LAAX) technology. Unlike other LAA technologies, which exclude or occlude the LAA, Laminar’s aims to completely eliminate it to treat AFib. Rather than use catheter-based devices to plug and occlude the LAA, Laminar’s approach utilizes rotational motion.
Irvine, California-based Biosense Webster commenced the patient cases as part of a pivotal FDA investigational device exemption (IDE) study. Dr. Saibal Kar (Los Robles Health System) and Dr. Devi Nair (St. Bernard’s Heart & Vascular Center) performed the procedures. Biosense Webster said they mark a “significant milestone” on the road to non-valvular AFib (NVAF) treatment.<…